Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Luci
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- -2.02
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -10.32
Financials
Net Income
$-2.25MEBITDA
$-2.31MFree Cash Flow
$-1.71MEPS (diluted)
$-0.53Shares Outstanding (diluted)
4.26M+792.9%Operating Expenses
$2.31MCash & Debt
$10.66MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-7.97M | $-5.32 |
| 2024 | $0.00 | $-14.10M | $-17.59 |
| 2023 | $0.00 | $-14.58M | $-23.01 |
| 2022 | $0.00 | $-12.09M | $-22.36 |
| 2021 | $0.00 | $-12.75M | $-24.96 |
| 2020 | $0.00 | $-4.60M | $-9.28 |
| 2019 | $0.00 | $-5.93M | $-12.00 |
Valuation
ACXPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-56.25%Social Signal Score
Mentions (4)
- Newsprnewswire.com·7d ago·Positive
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in the broader patient population for the treatment of acute CDI, has potential to shift the paradigm of treatment and prevention of rCDI
View source ↗ - Newsprnewswire.com·50d ago·Negative
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration progr
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·53d ago·Neutral
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.45 per share
Typical surprise -5.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.53 vs $-0.38miss
- Tue, May 12$-0.62 vs $-0.59miss
- Fri, Mar 13$-0.31 vs $-1.01beat
- Wed, Nov 12$-1.23 vs $-1.61beat
- Tue, Aug 12$-1.89 vs $-2.00beat
- Tue, May 13$-2.20 vs $-0.14miss
Estimates and results for ACXP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACXP officers and directors.
- Bought
- $615k
- Sold
- —
21 trades
0 trades
- Scodari Joseph Cbought
- Scodari Joseph Cbought
- Sailer Carlbought
- Sailer Carlbought
- Luci David Pbought
- Luci David Pbought
- Donohue James J.bought
- Donohue James J.bought
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACXP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.